Pralsetinib is a selective RET kinase inhibitor used as a targeted therapy for patients with RET mutation-positive medullary thyroid cancer and RET fusion-positive thyroid cancers that are refractory to… Read more

![Chemical structure of cis-1-Methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]cyclohexanecarboxylic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2778223-52-0-cis-1-Methoxy-4-4-methyl-6-5-methyl-1H-pyrazol-3-ylamino-2-pyrimidinylcyclohexanecarboxylic-Acid.png&w=3840&q=75)
![Chemical structure of Methyl cis-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]cyclohexanecarboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2778223-51-9-Methyl-cis-1-methoxy-4-4-methyl-6-5-methyl-1H-pyrazol-3-ylamino-2-pyrimidinylcyclohexanecarboxylate.png&w=3840&q=75)

Pralsetinib is a selective RET kinase inhibitor used as a targeted therapy for patients with RET mutation-positive medullary thyroid cancer and RET fusion-positive thyroid cancers that are refractory to radioactive iodine therapy. This category provides essential pharmaceutical reference standards, including the active pharmaceutical ingredient (API), related process impurities, and stable isotope-labelled compounds, which are critical for comprehensive analytical testing. Laboratories rely on these high-quality standards for rigorous impurity profiling and method validation, ensuring precise quantification and identity confirmation during formulation development and manufacturing. By utilizing these characterized reference materials, researchers can effectively monitor potential degradation pathways and verify the stability of the drug product. These materials facilitate accurate quality control assessments, supporting the maintenance of stringent regulatory compliance throughout the lifecycle of Pralsetinib development.